PTC Therapeutics Inc. [NASDAQ:PTCT] price is worthing noting Wednesday. The current price is $53.61 with a high of $54.13 and $51.85. Analysts see the the current price target is $61.18.
To ground this price against the rest of the market, over the last two 52 weeks, the company is trading 59.32%, while the S&P 500 is trading 1.71%. Traders should note that the company’s next earning date is 10/28/2020. The company has price per sales of 11.89.
The Price is right
Holding a Market Cap of $3.70 billion, PTC Therapeutics Inc. has seen a trading range over the last year of $30.79-$59.89.
For the last five days, PTCT is up from its last closing price. The average shares trading hands each day is 702.66K.
Using a Force Index Indicator is a good way to look at how strong actual buying and selling pressure is for PTCT. When we apply the Elder Force Index to PTC Therapeutics Inc., we are seeing an Elder Force Indicator number of 4279941.87.
Recent Performance
In the last quarter, PTCT made a profit of 69.94 million. PTC Therapeutics Inc. also saw quarter revenue growth year over year of 15.96%.
Technical Analysis
Looking at popular technical indicators, the company’s 5-day moving average is 50.02 compared to the 50-day moving average of 7.33%. So, we are clearly seeing an upward trajectory here.
The Relative Strength Index or RSI is an indicator ranging between 0 and 100 that traders use to determine if a stock is “overbought” or “oversold.” A strong uptrend tending to reach into the “overbought” status is above 70, while a downward trend will stay around the 30 mark. PTCT currently holds a 9-day RSI of 73.87%, while 100-day RSI stands at 52.39%.
Another indicator we believe is worth keeping tabs on is the Moving Average Convergence Divergence or MACD. Similar to the concept of the Force Index — on the basis of price momentum — the MACD gives traders a tool to measure the turning point of a stock even during rapid fluctuations in price. Buy and sell signals are determined by a stock’s relation to the zero line, so if a stock is above a zero line for many weeks it might be a “buy.” On the other hand, if a stock is below the zero line consistently, it might be one to stay away from. Also, if the MACD line reaches a peak and dips, its momentum may be waning. PTCT’s 9-day MACD is 2.36 and the company’s 100-day MACD stands at 1.41.
Inside Moves
Another area that is important to analyze is insider moves and majority shareholders. While this is not always an error-free way to tell what the future holds for a stock, you can maybe gather important information from reading the tea leaves about who is buying and selling.
The major holders for this stock are 3.21% by insiders and 99.32% by institutions. Regarding institutional holdings, Wellington Management Company, LLP owns 11.85%, while the second top holder, FMR, LLC, currently owns 9.89%.
Over the last six months, insiders have sold 124,351 with the most recent transaction from Peltz Stuart Walter, Chief Executive Officer, with a sell at price 50.12 per share.
Conclusion
Overall, the recommended rating for PTCT is Moderate Buy. Currently, the company has 12 analysts watching the stock, and the average quarterly earnings estimate is -0.04. Quarterly revenue estimates are averaging 111.88M with the high estimate reaching 129.95M and the low at 90M.
To review, the current 1-year target estimate is sitting at 60.20, while the current price 53.61. Based on this, we expect the stock to rise considering the aforementioned fundamentals.
